Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec 19;11(12):e0167906.
doi: 10.1371/journal.pone.0167906. eCollection 2016.

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

Cristiano Ferrario  1 , Ivan Strepponi  2 , Khashayar Esfahani  1 , Helen Charamis  1 , Adrian Langleben  1 , Emanuela Scarpi  3 , Oriana Nanni  3 , Wilson H Miller Jr  1 , Lawrence C Panasci  1
Affiliations
Clinical Trial

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

Cristiano Ferrario et al. PLoS One. .

Abstract

Background: Preclinical models have reported a synergistic interaction between sorafenib and vinorelbine. We investigated the toxicity, efficacy, and pharmacokinetics interaction of this combination as first-line treatment for patients with metastatic breast cancer.

Methods: Patients were HER2-negative and treated with vinorelbine 30 mg/m2 IV days 1,8 every 21 plus daily oral sorafenib. In the phase I portion (3+3 design) patients received sorafenib 200 mg BID (cohort 1) or 400 mg BID (cohort 2). In the phase II expansion, 21 more evaluable patients were planned to receive the maximum tolerated dose (MTD). Pharmacokinetic analysis was performed in 6 patients: blood concentrations were compared for each drug in the presence or absence of the other drug.

Results: In cohort 1, one patient experienced a dose-limiting toxicity (DLT) (grade 3 pancreatitis), requiring the expansion of this cohort to 6 patients, without further documented DLTs. In cohort 2, one patient of six experienced a grade 4 DLT (asymptomatic rise in amylase not requiring drug discontinuation), establishing this dose level as the MTD (sorafenib 400 mg BID). After expansion at the MTD, a total of 27 patients (median age 57) were treated for a median of 8 cycles. One grade 5 febrile neutropenia occurred. With repeated cycles, 52% of patients required at least 1 dose reduction of either drug. One patient experienced a sustained grade 3 fatigue resulting in treatment discontinuation. The response rate was 30%. Median PFS was 5.7 months (95% CI 4.4-7.6), and clinical benefit (absence of disease progression at 6 months) was 48%. PK analysis showed a significant interaction between the two drugs, resulting in a higher Cmax of vinorelbine in the presence of sorafenib.

Conclusion: The combination of sorafenib and vinorelbine at full doses is feasible but not devoid of toxicity, likely also due to a significant PK interaction.

Trial registration: ClinicalTrials.gov NCT00764972.

PubMed Disclaimer

Conflict of interest statement

The study was funded by Bayer Pharmaceutical. IS, ES, and ON are affiliated with Sede Secondaria Della Cell Therapeutics and helped provide statistical analysis for the study, without further conflict of interest, financial or other. These do not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Flow diagram of the patients enrolled in the study.
Fig 2
Fig 2. Progression-free survival of the VS combination
Fig 3
Fig 3. Progression-free survival by the dose of the regorafenib
Fig 4
Fig 4
A: Plasma concentration of Sorafenib over time. B: Plasma concentration of sorafenib metabolites (M2) over time
Fig 5
Fig 5. Mean plasma concentrations of vinorelbine when administered as a single agent (cycle 1 day 1, blue curve) or in the presence of steady-state concentrations of sorafenib (cycle 2 day 1, red curve).
See this image and copyright information in PMC

References

    1. Mano M. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer treatment reviews. 2006;32(2):106–18. Epub 2006/02/14. 10.1016/j.ctrv.2005.12.008 - DOI - PubMed
    1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research. 2004;64(19):7099–109. Epub 2004/10/07. 10.1158/0008-5472.CAN-04-1443 - DOI - PubMed
    1. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002;25(6):511–8. - PubMed
    1. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular cancer therapeutics. 2008;7(10):3129–40. Epub 2008/10/15. 10.1158/1535-7163.MCT-08-0013 - DOI - PubMed
    1. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer chemotherapy and pharmacology. 2007;59(2):183–95. 10.1007/s00280-006-0257-y - DOI - PubMed

Publication types

MeSH terms

Associated data